Literature DB >> 17982017

Neural substrate for atrial fibrillation: implications for targeted parasympathetic blockade in the posterior left atrium.

Rishi Arora1, Joseph S Ulphani, Roger Villuendas, Jason Ng, Laura Harvey, Sarah Thordson, Firdous Inderyas, Yi Lu, David Gordon, Pablo Denes, Rodney Greene, Susan Crawford, Robert Decker, Alexander Morris, Jeffrey Goldberger, Alan H Kadish.   

Abstract

The parasympathetic (P) nervous system is thought to contribute significantly to focal atrial fibrillation (AF). Thus we hypothesized that P nerve fibers [and related muscarinic (M(2)) receptors] are preferentially located in the posterior left atrium (PLA) and that selective cholinergic blockade in the PLA can be successfully performed to alter vagal AF substrate. The PLA, pulmonary veins (PVs), and left atrial appendage (LAA) from six dogs were immunostained for sympathetic (S) nerves, P nerves, and M(2) receptors. Epicardial electrophysiological mapping was performed in seven additional dogs. The PLA was the most richly innervated, with nerve bundles containing P and S fibers (0.9 +/- 1, 3.2 +/- 2.5, and 0.17 +/- 0.3/cm(2) in the PV, PLA, and LAA, respectively, P < 0.001); nerve bundles were located in fibrofatty tissue as well as in surrounding myocardium. P fibers predominated over S fibers within bundles (P-to-S ratio = 4.4, 7.2, and 5.8 in PV, PLA, and LAA, respectively). M(2) distribution was also most pronounced in the PLA (17.8 +/- 8.3, 14.3 +/- 7.3, and 14.5 +/- 8 M(2)-stained cells/cm(2) in the PLA, PV, and LAA, respectively, P = 0.012). Left cervical vagal stimulation (VS) caused significant effective refractory period shortening in all regions, with easily inducible AF. Topical application of 1% tropicamide to the PLA significantly attenuated VS-induced effective refractory period shortening in the PLA, PV, and LAA and decreased AF inducibility by 92% (P < 0.001). We conclude that 1) P fibers and M(2) receptors are preferentially located in the PLA, suggesting an important role for this region in creation of vagal AF substrate and 2) targeted P blockade in the PLA is feasible and results in attenuation of vagal responses in the entire left atrium and, consequently, a change in AF substrate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982017     DOI: 10.1152/ajpheart.00732.2007

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  25 in total

1.  Autonomic remodeling in the left atrium and pulmonary veins in heart failure: creation of a dynamic substrate for atrial fibrillation.

Authors:  Jason Ng; Roger Villuendas; Ivan Cokic; Jorge E Schliamser; David Gordon; Hemanth Koduri; Brandon Benefield; Julia Simon; S N Prasanna Murthy; Jon W Lomasney; J Andrew Wasserstrom; Jeffrey J Goldberger; Gary L Aistrup; Rishi Arora
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-03-18

Review 2.  Surgery for atrial fibrillation.

Authors:  Richard Lee; Jane Kruse; Patrick M McCarthy
Journal:  Nat Rev Cardiol       Date:  2009-08       Impact factor: 32.419

Review 3.  Role of the Auotnomic Nerves system in the Creation of Substrate for Atrial Fibrillation.

Authors:  Rishi Arora; Alan H Kadish
Journal:  J Atr Fibrillation       Date:  2008-12-01

Review 4.  Improving Atrial Fibrillation Therapy: Is There a Gene for That?

Authors:  William J Hucker; Alan Hanley; Patrick T Ellinor
Journal:  J Am Coll Cardiol       Date:  2017-04-25       Impact factor: 24.094

Review 5.  Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy.

Authors:  Peng-Sheng Chen; Lan S Chen; Michael C Fishbein; Shien-Fong Lin; Stanley Nattel
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

Review 6.  Mechanisms and Drug Development in Atrial Fibrillation.

Authors:  David Calvo; David Filgueiras-Rama; José Jalife
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

7.  Targeted nonviral gene-based inhibition of Gα(i/o)-mediated vagal signaling in the posterior left atrium decreases vagal-induced atrial fibrillation.

Authors:  Gary L Aistrup; Ivan Cokic; Jason Ng; David Gordon; Hemanth Koduri; Suzanne Browne; Dorina Arapi; Yogita Segon; Jacob Goldstein; Abigail Angulo; J Andrew Wasserstrom; Jeffrey J Goldberger; Alan H Kadish; Rishi Arora
Journal:  Heart Rhythm       Date:  2011-08-25       Impact factor: 6.343

Review 8.  Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: implications for therapies targeting the atrial autonomic nervous system.

Authors:  Rishi Arora
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-08-01

9.  Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease.

Authors:  Helen Kiriazis; Nicole L Jennings; Pamela Davern; Gavin Lambert; Yidan Su; Terence Pang; Xin Du; Luisa La Greca; Geoffrey A Head; Anthony J Hannan; Xiao-Jun Du
Journal:  J Physiol       Date:  2012-08-13       Impact factor: 5.182

10.  Targeted G-protein inhibition as a novel approach to decrease vagal atrial fibrillation by selective parasympathetic attenuation.

Authors:  Gary L Aistrup; Roger Villuendas; Jason Ng; Annette Gilchrist; Thomas W Lynch; David Gordon; Ivan Cokic; Steven Mottl; Rui Zhou; David A Dean; J Andrew Wasserstrom; Jeffrey J Goldberger; Alan H Kadish; Rishi Arora
Journal:  Cardiovasc Res       Date:  2009-05-20       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.